GRCE insider buying & filings

← All candidates

GRCEGrace Therapeutics, Inc.

NasdaqCM · Healthcare · $46.91M

$2.23

-2.62% · Sep 15

Two insiders bought $245.9K in two days.
Led by Kohli Prashant, chief executive officer.

Last Form 4 Sep 10 · scanned 2m ago

Price · 1Y · daily● 4 buys◆ 8 8-K

▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained

Reverse-split 3×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what GRCE ever actually traded at. The drop is real, but those huge old numbers aren't.

AI brief · from the filings on this pagePro

The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.

▸ Included with Pro →

Market cap

$46.91M

Float

15.5M

74% public

Short % float

Pro

The buyers

▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions

Chief Executive Officer

Kohli Prashant

Bought $214.0K on Sep 9 — 100,000 sh @ $2.14, held direct, 82% of their stake.

First Form 4 on file

no positions we can measure against the market — the record starts here

10% owner

Opaleye Management Inc.

Bought $24.2K on Aug 14 — 11,608 sh @ $2.09, held indirect, 0.4% of their stake.

2 of 5 positions beat the S&P

median -1.7% vs S&P +12.8% same spans · 63 buy-days · 2 positions still open

Institutional stakes

▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing

2 filingsnewest first

13G/AADAR1 Capital Management, LLC9.9%Aug 14

13GOpaleye Management Inc.13.1%Aug 7

The record

newest first

DateTypeInsiderOf stakeShares @ priceValue

Sep 10BUYOpaleye Management Inc.10% owner+0.2%indirect5,836 @ $2.09$12.2K

Sep 10BUYOpaleye Management Inc.10% owner+0.3%indirect9,393 @ $2.10$19.7K

Sep 10BUYKohli PrashantChief Executive Officer+82%direct100,000 @ $2.14$214.0K

Aug 19BUYOpaleye Management Inc.10% owner+0.4%indirect11,608 @ $2.09$24.2K

Context

Wall St

$6.03 avg target

+170.6% vs today · 2 analysts

▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice

Earnings · EPS vs forecast

4 of 4 quarters beat

Q2 '26−$0.18 act+$0.00

Q1 '26−$0.08 act+$0.12

Q4 '25−$0.19 act+$0.20

Q3 '25−$0.08 act+$0.26

Coverage

We're Not Very Worried About Grace Therapeutics' (NASDAQ:GRCE) Cash Burn RateSimply Wall St. · 04-04 This Grace Therapeutics Insider Increased Their Holding By 12% Last YearSimply Wall St. · 11-01 We Think Grace Therapeutics (NASDAQ:GRCE) Needs To Drive Business Growth CarefullySimply Wall St. · 09-23 Sector Update: Health Care Stocks Edge Lower Late AfternoonMT Newswires · 04-23

The file stays open

9 filings on record.
The next one will be too.

All candidates

▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice

Kohli Prashant

Opaleye Management Inc.

9 filings on record.The next one will be too.

9 filings on record.
The next one will be too.